FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Rozenman Mary M.   2. Issuer Name and Ticker or Trading Symbol Aimmune Therapeutics, Inc. [AIMT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300 3. Date of Earliest Transaction (Month/Day/Year) 12/26/2017 (Street) BRISBANE, CA 94005-1884 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.0001 par value 12/26/2017   M   75,010 A $ 3.022 75,139 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   11,000 D $ 38.8263 (2) 64,139 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   1,500 D $ 39.252 (3) 62,639 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   10,700 D $ 38.8151 (2) 51,939 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   1,800 D $ 39.225 (4) 50,139 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   11,000 D $ 38.8286 (5) 39,139 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   1,500 D $ 39.25 (6) 37,639 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   11,000 D $ 38.8221 (7) 26,639 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   1,500 D $ 39.2313 (8) 25,139 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   4,310 D $ 38.8026 (9) 20,829 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   700 D $ 39.2557 (10) 20,129 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   8,800 D $ 38.8253 (11) 11,329 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   1,200 D $ 39.2783 (12) 10,129 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   6,400 D $ 38.7263 (13) 3,729 D   Common Stock, $0.0001 par value 12/26/2017   S(1)   3,600 D $ 39.1526 (14) 129 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy)

$ 3.022

12/26/2017

M

75,010

(15)

04/17/2025

Common Stock

75,010

$ 0

120,426

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Rozenman Mary M. AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE, CA 94005-1884			See Remarks

Signatures

/s/ Douglas T. Sheehy, as Attorney-in-Fact for Mary M. Rozenman		12/28/2017
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
(2)	The transaction was executed in multiple trades in prices ranging from $38.13 to $39.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(3)	The transaction was executed in multiple trades in prices ranging from $39.14 to $39.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(4)	The transaction was executed in multiple trades in prices ranging from $39.14 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(5)	The transaction was executed in multiple trades in prices ranging from $38.14 to $39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(6)	The transaction was executed in multiple trades in prices ranging from $39.15 to $39.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(7)	The transaction was executed in multiple trades in prices ranging from $38.12 to $39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(8)	The transaction was executed in multiple trades in prices ranging from $39.13 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(9)	The transaction was executed in multiple trades in prices ranging from $38.14 to $39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(10)	The transaction was executed in multiple trades in prices ranging from $39.15 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(11)	The transaction was executed in multiple trades in prices ranging from $38.15 to $39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(12)	The transaction was executed in multiple trades in prices ranging from $39.16 to $39.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(13)	The transaction was executed in multiple trades in prices ranging from $38.06 to $39.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(14)	The transaction was executed in multiple trades in prices ranging from $39.07 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(15)	The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Remarks: Senior VP, Corporate Development and Strategy

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.